InMed Pharmaceuticals (INM) Liabilities and Shareholders Equity (2020 - 2026)

InMed Pharmaceuticals has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $9.1 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 1.57% year-over-year to $9.1 million; the trailing twelve-month figure through Mar 2026 stood at $49.3 million (up 22.95% YoY), and the FY2025 full-year result was $15.6 million, up 31.78% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $9.1 million, down from $11.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $16.9 million in Q4 2022, with the low at $8.5 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $12.8 million across 5 years, with a median of $13.4 million in 2024.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity plunged 44.27% — and 2025, when it soared 31.78%.
• InMed Pharmaceuticals' Liabilities and Shareholders Equity stood at $16.9 million in 2022, then fell by 9.84% to $15.3 million in 2023, then sank by 44.27% to $8.5 million in 2024, then jumped by 31.63% to $11.2 million in 2025, then retreated by 18.39% to $9.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $9.1 million (Q1 2026), $11.2 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.